The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

Sep 25, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg, DE, about allogeneic stem cell transplantation (allo-SCT). We asked, At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

Unlike autologous-SCT, allo-SCT has not become a standard of care for the treatment of MM. However, long term data exist showing that allo-SCT has the potential to be curative. At the same time, SCT-associated morbidity and mortality can be high, highlighting the importance of patient selection. Nicolaus Kröger discusses the results from several studies comparing auto-SCT with allo-SCT.